Bronchogen (Ala-Glu-Asp-Leu) is a synthetic bioregulatory tetrapeptide designed to target lung tissue, enhancing respiratory health and structural integrity.
It shows strong affinity for bronchial epithelium, demonstrating anti-inflammatory and regenerative effects in studies.
It is primarily used in research to study cellular regeneration, typically in lyophilized form.
Primary Research Areas
Studies on Bronchogen, often led by researcher Vladimir Khavinson, focus on its potential impact on the respiratory system:
- Lung Repair: It has been studied in rat models for its ability to reduce inflammation and promote the repair of bronchial epithelium in conditions like chronic obstructive pulmonary disease (COPD).
- Anti-Inflammatory: In experimental models, it has been shown to normalize the profile of pro-inflammatory cytokines and increase markers for local immunity, such as secretory immunoglobulin A.
- DNA Stability: Research suggests it can serve as a DNA-stabilizing agent, potentially reversing age-related declines in lung cell function at the genetic level.
For research use only, not to be used in clinical trials involving humans. Documentation is for information only.